Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Exclusion Criteria

• •1. DLBCL with central nervous system (CNS) involvement with active brain or leptomeningeal disease
• •2. Known human immunodeficiency (HIV; testing not required) or HIV-related malignancy
• •3. Known hepatitis B surface antigen positive or known or active hepatitis C infection
• •4. Prior autologous stem cell transplant (ASCT) or chimeric antigen receptor T-cell (CAR-T) cell infusion within 90 days of screening
• •5. Prior allogeneic stem cell transplantation
• •6. Unstable/inadequate cardiac function
• •7. Known gastrointestinal (GI) disease or GI procedure that interferes with swallowing/absorption of oral drug
• •8. Major surgery within 14 days before the first dose of study drug
• •9. Serious infection (bacterial/fungal/viral) requiring parenteral antibiotic/antiviral therapy for \>5 days within 21 days prior to first dose of study drug
• •10. Treatment with high-dose corticosteroids for anticancer purposes within 7 days before the first dose of mivavotinib.
• •11. Use of medication known to be inhibitors or inducers of P-glycoprotein (P-gp) and/or Cytochrome P (CYP)3A
• •12. Female patients who are pregnant, lactating or breastfeeding.
• •13. Any radiation therapy within 3 weeks prior to first dose of study treatment.
• •14. Systemic anticancer treatment within 3 weeks before first dose of study treatment